Meeting
2022 ASCO Annual Meeting
Matching-adjusted indirect comparison (MAIC) of mobocertinib versus amivantamab in patients with non–small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins).
Presenter
Sai-Hong Ignatius Ou, MD, PhD
Chao Family Comprehensive Cancer Center, University of California Irvine
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02716116
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9115)
DOI
10.1200/JCO.2022.40.16_suppl.9115
Abstract #
9115
Poster Bd #
101
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2023 ASCO Annual Meeting
Mobocertinib efficacy in patients with NSCLC and EGFR exon 20 insertion mutations (ex20ins) identified by next-generation sequencing (NGS) of circulating tumor DNA (ctDNA).
Speaker: Joel W. Neal, MD, PhD
Videos & Slides
2021 ASCO Annual Meeting
Amivantamab compared with real-world therapies in patients with NSCLC with EGFR Exon 20 insertion mutations who have progressed after platinum doublet chemotherapy.
Speaker: Anna Rachel Minchom, BCh, MB, MD, MRCP
Videos & Slides
2020 ASCO Virtual Scientific Program
Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC).
Speaker: Keunchil Park, MD, PhD
Speaker: Anthony Cmelak, MD